Shopping Cart
- Remove All
- Your shopping cart is currently empty
IL-1RA Protein, Human, Recombinant (HEK293) is expressed in HEK293 Cells. The accession number is P18510.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 μg | $85 | 7-10 days | |
50 μg | $170 | 7-10 days | |
1 mg | $1,690 | 7-10 days |
Biological Activity | ED 50 < 0.1 μg /ml, measured in a neutralization assay using D10S cells in the presence of 50.0 pg/ml Human IL-1a. |
Description | IL-1RA Protein, Human, Recombinant (HEK293) is expressed in HEK293 Cells. The accession number is P18510. |
Species | Human |
Expression System | HEK293 Cells |
Tag | Tag Free |
Accession Number | P18510 |
Synonyms | IRAP,IL-1RN,IL1RA,ICIL-1RA |
Construction | Arg26-Glu177 |
Protein Purity | > 95% as determined by SDS-PAGE; > 95% as determined by HPLC |
Molecular Weight | 18~23 kDa (Reducing conditions) |
Endotoxin | < 0.2 EU/μg of protein as determined by the LAL method. |
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
Reconstitution | Reconstitute the lyophilized protein in sterile deionized water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing. |
Stability & Storage | Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
Shipping | In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. |
Research Background | IL-1 Receptor Antagonist, also known as IL-1RA, ICIL-1RA, IRAP and IL-1RN, is a member of the interleukin 1 cytokine family. It is expressed by monocytes, neutrophils, macrophages, epithelial cells and fibroblasts. IL-1RA inhibits the activity of both IL-1alpha and IL-1beta, and modulates a variety of IL-1 related immune and inflammatory responses. It inhibits the activity of IL-1 by binding to the receptor IL-1R1 and preventing its association with the coreceptor IL-1RAP for signaling. Clinical studies are being conducted to investigate the use of IL-1RA in the treatment of sepsis, rheumatoid arthritis and chronic myelogenous leukemia. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.